论文部分内容阅读
目的研究神经母细胞瘤患儿血清肿瘤标志物水平变化的表达,为临床诊治提供依据。方法选取2014-02-2016-02医院诊治的神经母细胞瘤患儿54例,采用ELISA方法检测患儿血清神经元特异性烯醇化酶(neuron-specific enolase,NSE)和血清铁蛋白(ferritin,SF)水平,采用全自动生化分析仪利用速率法测定血清乳酸脱氢酶(lactate dehydrogen,LDH)水平,分析神经母细胞瘤患儿不同分期、治疗前后血清肿瘤标志物水平变化的表达情况。结果入选患儿肿瘤分期Ⅰ~Ⅱ期者NSE、SF及LDH水平,显著低于对照组Ⅲ~Ⅳ期患者,P<0.05;入选患儿治疗后血清肿瘤标志物NSE、SF及LDH水平显著低于治疗前,P<0.05。结论神经母细胞瘤患儿不同分期、治疗前后血清肿瘤标志物水平变化存在明显差异,动态监测血清肿瘤标志物水平能指导患儿预后、治疗。
Objective To study the expression of serum tumor markers in children with neuroblastoma and to provide evidence for clinical diagnosis and treatment. Methods 54 children with neuroblastoma diagnosed in hospital from February 2014 to February 2016 were enrolled in this study. Serum levels of neuron-specific enolase (NSE) and serum ferritin SF), serum lactate dehydrogen (LDH) levels were measured by the rate method with automatic biochemical analyzer. The levels of serum tumor markers in different stages of neuroblastoma were analyzed before and after treatment. Results The levels of NSE, SF and LDH in stage Ⅰ ~ Ⅱ of children with stage Ⅲ were significantly lower than those in stage Ⅲ ~ Ⅳ of the control group (P <0.05). The serum levels of NSE, SF and LDH were significantly lower Before treatment, P <0.05. Conclusion There are significant differences in the levels of serum tumor markers between different stages of neuroblastoma before and after treatment. The dynamic monitoring of serum tumor markers can guide the prognosis and treatment of children.